

**Africure Pharmaceuticals Ltd**

(Incorporated in the Republic of Mauritius)

(Registration number: C145852 C1/GBL)

Having its registered address at

6th Floor, Tower A, 1 Cybercity, Ebene, Republic of Mauritius

(“Africure” or “the Company”)



[Africure and its subsidiaries are collectively referred to as the “Group”]

---

**FURTHER EXTENSION OF DEADLINE TO RELEASE UNAUDITED FINANCIAL RESULTS**

---

Shareholders of Africure and interested parties are referred to the communique released by the Company on 10 February 2025 wherein the Board of directors of Africure (the “**Board**”) had announced that the Stock Exchange of Mauritius (“**SEM**”) approved the extension of the deadline for publishing the Company’s abridged unaudited financial statements for the three months and nine months ended 31 December 2024 until 28 February 2025.

Due to the unavailability of directors to form a quorum, the Board is unable to hold a board meeting within the extended deadline of 28 February 2025, at which the unaudited consolidated financial statements for the three months and nine months ended 31 December 2024 would have been considered and approved for release.

Consequently, and following an application made to the SEM, the Company has obtained formal approval of the SEM to further extend the deadline for publishing its abridged unaudited consolidated financial statements for the three months and nine months ended 31 December 2024, until 14 March 2025.

By order of the Board

25 February 2025

For further information please contact:

**SEM Authorised Representative & Sponsor**



+230 402 0890

**Company Secretary**



+230 403 6000

---

*This notice is issued pursuant to SEM Listing Rule 11.3. The Board of Africure accepts full responsibility for the accuracy of the information contained in this announcement.*